載入...
Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC
Lung adenocarcinoma is the most common subtype of lung cancer today. With the discovery of epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, and effective targeted therapy, personalized medicine has become a reality for patients with lung adenocarcin...
Na minha lista:
| 發表在: | Front Oncol |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Frontiers Media S.A.
2014
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4243502/ https://ncbi.nlm.nih.gov/pubmed/25505733 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2014.00329 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|